Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective:

Secondary Objective:

Study of SAR339375 in Patients With Alport Syndrome

Primary Objectives:

Secondary Objectives:

Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives:

Secondary Objectives:

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

ul>

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

ul>

Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3

ul>

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives:

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives:

Systematic Evaluation of Ablation Techniques for Non-Paroxysmal Atrial Fibrillation.

The purpose of this study is to evaluate the safety and effectiveness of empirical posterior wall isolation (PWI), left atrial appendage electrical isolation (LAAEI) and coronary sinus isolation (CSI) when compared to pulmonary vein isolation (PVI) alone:

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective:

To characterize the long-term safety and tolerability of fitusiran

Secondary Objectives: